CA2474322A1 - (thia-/oxa-/pyra) zoles substitues 4(hetero-) aryle pour inhibition de tie-2 - Google Patents

(thia-/oxa-/pyra) zoles substitues 4(hetero-) aryle pour inhibition de tie-2 Download PDF

Info

Publication number
CA2474322A1
CA2474322A1 CA002474322A CA2474322A CA2474322A1 CA 2474322 A1 CA2474322 A1 CA 2474322A1 CA 002474322 A CA002474322 A CA 002474322A CA 2474322 A CA2474322 A CA 2474322A CA 2474322 A1 CA2474322 A1 CA 2474322A1
Authority
CA
Canada
Prior art keywords
mmol
hplc
group
general procedure
ethanol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002474322A
Other languages
English (en)
Inventor
Frank Stieber
Klaus Hellmuth
Herbert Waldmann
Ralph Mazitschek
Athanassios Giannis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
KYLIX PHARMACEUTICALS BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/057,747 external-priority patent/US20030158199A1/en
Application filed by KYLIX PHARMACEUTICALS BV filed Critical KYLIX PHARMACEUTICALS BV
Publication of CA2474322A1 publication Critical patent/CA2474322A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Cette invention concerne un composé représenté par la formule (I), dans laquelle V est H ou, ou bien ; R¿1? peut être indépendamment H, alkyle, alcényle, cycloalkyle, hétéroalkyle, aryle, hétéroaryle, arylalkyle, alkylaryle, N-R¿6?R¿7?, N- (CO) R¿6?R¿7?, N-R¿6? (CO) R¿7 ?ou N- (CO) -O-R¿6?R¿7 ?; R¿8? peut être indépendamment H, alkyle, alcényle, cycloalkyle, hétéroalkyle, aryle, hétéroaryle, arylalkyle, alkylaryle, N-R¿3?R¿4?, N- (CO) R¿3?R¿4?, N-R¿3? (CO) R¿4?, N- (CO) -O-R¿3?R¿4?, O-R¿3?, CO-R¿3?, CO-OR¿3? ou O-CO-R¿3 ?; R¿2?, R¿5? peuvent être indépendamment H, alkyle, alcényle, cycloalkyle, hétéroalkyle, aryle, hétéroaryle, arylalkyle, alkylaryle, carboxyle, Br, C1, F, CF¿3 ?; R¿3?, R¿4?, R¿6?, R¿7 ?peuvent être indépendamment H, alkyle, alcényle, cycloalkyle, hétéroalkyle, aryle, hétéroaryle, arylalkyle, alkylaryle, COOR¿5? et CO-R¿5?, et peuvent former une structure en anneau ; X, Y, Z peuvent être indépendamment CH ou N ; et U peut être indépendamment S ou NH ;W peut être indépendamment NH, O ou S, et des mélanges racémiques-diastereomériques, des isomères optiques, et des sels de ce composé acceptables au plan pharmaceutique. L'invention concerne une méthode permettant d'inhiber l'activité d'une ou de plusieurs protéines kinases à l'aide de ces composés, in vitro ou en culture cellulaire, ainsi qu'une composition pharmaceutique comprenant un tel composé et son utilisation médicamenteuse.
CA002474322A 2002-01-25 2003-01-27 (thia-/oxa-/pyra) zoles substitues 4(hetero-) aryle pour inhibition de tie-2 Abandoned CA2474322A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10/057,747 2002-01-25
US10/057,747 US20030158199A1 (en) 2002-01-25 2002-01-25 Novel compounds for inhibition of Tie-2
EP02075367 2002-01-25
EP02075367.9 2002-01-25
PCT/EP2003/000810 WO2003062215A1 (fr) 2002-01-25 2003-01-27 (thia-/oxa-/pyra) zoles substitues 4(hetero-) aryle pour inhibition de tie-2

Publications (1)

Publication Number Publication Date
CA2474322A1 true CA2474322A1 (fr) 2003-07-31

Family

ID=27614618

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002474322A Abandoned CA2474322A1 (fr) 2002-01-25 2003-01-27 (thia-/oxa-/pyra) zoles substitues 4(hetero-) aryle pour inhibition de tie-2

Country Status (3)

Country Link
EP (1) EP1467981A1 (fr)
CA (1) CA2474322A1 (fr)
WO (1) WO2003062215A1 (fr)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003003006A2 (fr) 2001-06-29 2003-01-09 Ab Science Nouveaux inhibiteurs selectifs puissants et non toxiques de c-kit
PT1401416E (pt) 2001-06-29 2007-02-28 Ab Science Utilização de inibidores de c-kit para tratar doenças inflamatórias intestinais (dii)
ATE330608T1 (de) 2001-06-29 2006-07-15 Ab Science Die verwendung von n-phenyl-2-pyrimidine-amine derivaten zur behandlung von entzündlichen erkrankungen
ES2274993T3 (es) 2001-06-29 2007-06-01 Ab Science Utilizacion de inhibidores de tirosina cinasa para el tratamiento de enfermedades alergicas.
MXPA05001277A (es) 2002-08-02 2005-10-06 Ab Science 2-(3-aminoaril)amino-4-aril-tiazoles y su uso como inhibidores del c-kit.
US8450302B2 (en) 2002-08-02 2013-05-28 Ab Science 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors
GB0326601D0 (en) * 2003-11-14 2003-12-17 Novartis Ag Organic compounds
TWI349550B (en) 2003-12-26 2011-10-01 A thiazole derivative and adenosine a2a receptor antagonist containing the same
EP1555264A1 (fr) * 2004-01-15 2005-07-20 Sireen AG Hétérocycles à cinq chaínons comme inhibiteurs de la famille des SRC proteines kinases
TWI332003B (en) 2004-01-30 2010-10-21 Lilly Co Eli Kinase inhibitors
CN1934107A (zh) * 2004-01-30 2007-03-21 Ab科学公司 作为酪氨酸激酶抑制剂的2－(3－取代芳基)氨基－4－芳基－噻唑
NZ549003A (en) 2004-03-05 2009-07-31 Taisho Pharmaceutical Co Ltd Thiazole derivative as an ALK5 inhibitor
BRPI0515012A (pt) 2004-08-13 2008-07-01 Genentech Inc substáncia quìmica, composição e formulação farmacêutica, método de tratamento, método de inibição de pelo menos uma enzima que utiliza atp e uso
MX2007012392A (es) * 2005-04-04 2007-12-05 Ab Science Derivados de oxazol sustituidos y su uso como inhibidores de tirosina cinasa.
AU2006244203B2 (en) 2005-05-09 2012-05-03 Achillion Pharmaceuticals, Inc. Thiazole compounds and methods of use
EP1888546B1 (fr) * 2005-05-24 2015-07-08 Merck Serono SA Derives thiazole et utilisation
EP1894930A4 (fr) 2005-06-23 2010-06-23 Kyowa Hakko Kirin Co Ltd Dérivé du thiazole
AU2006290814B2 (en) * 2005-09-13 2012-06-07 Janssen Pharmaceutica N.V. 2-aniline-4-aryl substituted thiazole derivatives
JO2769B1 (en) 2005-10-26 2014-03-15 جانسين فارماسوتيكا ان. في Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor
PT2402319T (pt) 2006-03-31 2017-12-11 Novartis Ag Inibidores de dgat
EP2032562B1 (fr) 2006-05-12 2010-08-25 Vertex Pharmaceuticals Incorporated Inhibiteurs sélectifs de protéine kinase rock et utilisations de ceux-ci
JO2642B1 (en) 2006-12-08 2012-06-17 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
JO2849B1 (en) 2007-02-13 2015-03-15 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
JP5431305B2 (ja) 2007-04-23 2014-03-05 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 高速解離性ドパミン２受容体アンタゴニストとしての４−アルコキシピリダジン誘導体
RU2489431C2 (ru) 2007-04-23 2013-08-10 Янссен Фармацевтика Н.В. Тиа(диа)золы как быстро диссоциирующие антагонисты рецептора допамина 2
EA200901573A1 (ru) 2007-05-22 2010-04-30 Ачиллион Фармасьютикалз, Инк. Гетероарилзамещенные тиазолы
JO2784B1 (en) 2007-10-18 2014-03-15 شركة جانسين فارماسوتيكا ان. في 5,3,1 - Triazole substitute derivative
JP2011500625A (ja) 2007-10-18 2011-01-06 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ トリ置換された１，２，４−トリアゾール
AR070936A1 (es) 2008-03-19 2010-05-12 Janssen Pharmaceutica Nv 1,2,4 -triazoles trisustituidos
EP2107054A1 (fr) * 2008-04-01 2009-10-07 Università Degli Studi Di Milano - Bicocca Composés antiprolifératives et ses utilisations thérapeutiques
JP5486591B2 (ja) 2008-05-09 2014-05-07 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ アセチルコリン受容体モジュレーターとしての三置換ピラゾール
US8106209B2 (en) 2008-06-06 2012-01-31 Achillion Pharmaceuticals, Inc. Substituted aminothiazole prodrugs of compounds with anti-HCV activity
WO2010008831A2 (fr) * 2008-06-24 2010-01-21 Irm Llc Composés et procédés pour moduler les récepteurs couplés à la protéine g
JP5417439B2 (ja) 2008-07-03 2014-02-12 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ５−ｈｔ６受容体アンタゴニストとしての置換された６−（１−ピペラジニル）−ピリダジン類
EA019048B1 (ru) 2008-07-31 2013-12-30 Янссен Фармацевтика Нв Пиперазин-1-илтрифторметилзамещенные пиридины в качестве быстро диссоциирующихся антагонистов d-рецепторов дофамина
EP2166006A1 (fr) * 2008-09-18 2010-03-24 Dompe' S.P.A. Acides 2-aryl-propioniques et dérivés et compositions pharmaceutiques les contenant
WO2012162461A1 (fr) * 2011-05-25 2012-11-29 Janssen Pharmaceutica Nv Inhibiteurs phényle-thiazolylés de l'activation de pro-métalloprotéinase de matrice
WO2015002926A1 (fr) 2013-07-02 2015-01-08 Bristol-Myers Squibb Company Dérivés pyrido-carboxamides tricycliques servant d'inhibiteurs de rock
JP6434968B2 (ja) 2013-07-02 2018-12-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｒｏｃｋ阻害剤としての三環式ピリド−カルボキサミド誘導体
US9453002B2 (en) 2013-08-16 2016-09-27 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers
US9828351B2 (en) * 2014-06-26 2017-11-28 Monash University Enzyme interacting agents
JP6424068B2 (ja) * 2014-11-06 2018-11-14 東友ファインケム株式会社Ｄｏｎｇｗｏｏ Ｆｉｎｅ−Ｃｈｅｍ Ｃｏ．， Ｌｔｄ． 化合物
EP3259256B1 (fr) * 2015-02-17 2022-03-09 Beijing Erai Therapeutics Co., Ltd. Composés et méthodes destinés à induire le brunissement du tissu adipeux blanc
US10696638B2 (en) 2017-12-26 2020-06-30 Industrial Technology Research Institute Compounds for inhibiting AGC kinase and pharmaceutical compositions comprising the same
US11472781B2 (en) 2018-02-21 2022-10-18 Southern Research Institute 2-aminoaryl-5-aryloxazole analogs for the treatment of neurodegenerative diseases
CR20200464A (es) 2018-03-08 2021-04-14 Incyte Corp Compuestos diólicos de aminopirazina como inhibidores de pi3k-y
US11718593B2 (en) * 2018-05-17 2023-08-08 Southern Research Institute 2,5-aryl-thiazole analogs for the treatment of neurodegenerative diseases
WO2020010003A1 (fr) 2018-07-02 2020-01-09 Incyte Corporation DÉRIVÉS D'AMINOPYRAZINE UTILISÉS EN TANT QU'INHIBITEURS DE PI3K-γ
EP3846793B1 (fr) 2018-09-07 2024-01-24 PIC Therapeutics, Inc. Inhibiteurs d'eif4e et leurs utilisations
AR121506A1 (es) 2020-03-03 2022-06-08 Pic Therapeutics Inc Inhibidores del eif4e y sus usos
IL310924A (en) 2021-08-25 2024-04-01 Pic Therapeutics Inc Eif4e inhibitors and uses thereof
US12157732B2 (en) 2021-08-25 2024-12-03 PIC Therapeutics, Inc. eIF4E inhibitors and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6228871B1 (en) * 1995-07-10 2001-05-08 Merck & Co., Inc. Angiogenesis inhibitors
UA71971C2 (en) * 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
MXPA02002559A (es) * 1999-09-10 2002-07-30 Merck & Co Inc Inhibidores de tirosina cinasa.

Also Published As

Publication number Publication date
EP1467981A1 (fr) 2004-10-20
WO2003062215A1 (fr) 2003-07-31

Similar Documents

Publication Publication Date Title
EP1467981A1 (fr) (thia-/oxa-/pyra) zoles substitues 4(hetero-) aryle pour inhibition de tie-2
US20030158199A1 (en) Novel compounds for inhibition of Tie-2
RU2456285C2 (ru) Способ получения соединений 2-аминотиазола в качестве ингибиторов киназы
ES2315566T3 (es) Tiazolidin-4-onas para inhibir proteinas hyak3.
TWI473792B (zh) New quinoline compounds and their use
JP3785397B2 (ja) ５員環化合物
JP5463592B2 (ja) アデノシンａ１レセプターアンタゴニストとしての新規化合物
JP6713928B2 (ja) Ｕｒａｔ１阻害剤
WO2011085128A1 (fr) Inhibiteurs de la voie hedgehog
WO2003105842A1 (fr) Derives de chromen-2-one utilises comme inhibiteurs de la production des vegf dans les cellules mammaliennes
JP6095195B2 (ja) 新規二環式チアゾール化合物
US6391894B1 (en) Myt1 kinase inhibitors
US6448272B1 (en) Myt1 kinase inhibitors
AU2003236875A1 (en) 4(hetero-) aryl substituted (thia-/oxa-/pyra) zoles for inhibition of tie-2
CA3026252A1 (fr) Inhibiteurs de l'autotaxine
JP2006169257A (ja) ５員環化合物
AU2766100A (en) Myt1 kinase inhibitors
NZ503917A (en) Bis thiazole amine derivatives useful as Myt1 kinase inhibitors

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead